Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-26T14:30:43.056Z Has data issue: false hasContentIssue false
  • English
  • Français

Mesalamine-induced myopericarditis in a paediatric patient with Crohn’s disease

Published online by Cambridge University Press:  10 June 2014

Asha G. Nair Open the ORCID record for Asha G. Nair [Opens in a new window]  and
Russell R. Cross
Asha G. Nair*
Affiliation:
Division of Cardiology, Children’s National Medical Center, Washington, District of Columbia, United States of America
Russell R. Cross
Affiliation:
Division of Cardiology, Children’s National Medical Center, Washington, District of Columbia, United States of America
*
Correspondence to: Dr A. G. Nair, MD, Children’s National Medical Center, 111 Michigan Avenue, N.W., Washington, DC 20010, United States of America. Tel: +(202) 476-2020; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Mesalamine-containing products are considered first-line treatment for inflammatory bowel disease. Myocarditis is recognised as a very rare possible side effect of these medications, but has not often been described in the paediatric population. We present a case of an adolescent with Crohn’s disease who presented with myopericarditis after recent initiation of Pentasa. Once identified as the causative agent, the drug was discontinued, with subsequent normalisation of troponin and improvement of function. This case identifies the importance of prompt evaluation, diagnosis, and treatment of paediatric patients receiving mesalamine-containing medications that present with significant cardiovascular symptoms.

Keywords

MyocarditismesalamineCrohn’s disease
Type
Brief Reports
Information
Cardiology in the Young , Volume 25 , Issue 4 , April 2015 , pp. 783 - 786
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Bernstein, CN, Fried, M, Krabshuis, JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010; 16: 112–124.Google Scholar
2. Schroeder, KW. Is mesalamine safe? Gastroenterol Hepatol 2007; 3: 878–879.Google Scholar
3. Atay, O, Radhakrishnan, K, Arruda, J, et al. Severe chest pain in a pediatric ulcerative colitis patient after 5-aminosalicylic acid therapy. World J Gastroenterol 2008; 14: 4400–4402.Google Scholar
4. Merceron, O, Bailly, C, Khalil, A, et al. Mesalamine-induced myocarditis. Cardiol Res Pract 2010; 2010: 3pp.Google Scholar
5. Perez-Colon, E, Dadlani, GH, Wilmot, I, et al. Mesalamine-induced myocarditis and coronary vasculitis in a pediatric ulcerative colitis patient: a case report. Case Rep Pediatr 2011; 2011: 524364.Google Scholar
6. Waite, RA, Malinowski, JM. Possible mesalamine-induced pericarditis: case report and literature review. Pharmacotherapy 2002; 22: 391–394.Google Scholar
7. Rabizadeh, S, Dubinsky, M. Update in pediatric inflammatory bowel disease. Rheum Dis Clin North Am 2013; 39: 789–799.CrossRefGoogle ScholarPubMed
8. Ha, C, Magowan, S, Accortt, NA, et al. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol 2009; 104: 1445–1451.Google Scholar